Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

562 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emotional Effects on Factors Associated with Chronic Low Back Pain.
Ouchi K, Watanabe M, Tomiyama C, Nikaido T, Oh Z, Hirano T, Akazawa K, Mandai N. Ouchi K, et al. Among authors: akazawa k. J Pain Res. 2019 Dec 17;12:3343-3353. doi: 10.2147/JPR.S223190. eCollection 2019. J Pain Res. 2019. PMID: 31908519 Free PMC article.
Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.
Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino H, Yamada K, Narui K, Kimura K, Akazawa K, Kohno N; JONIE STUDY GROUP. Hayashi M, et al. Among authors: akazawa k. Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596. Anticancer Res. 2019. PMID: 31366522 Clinical Trial.
Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.
Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M, Moriyama H, Takada T, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Arai T, Sugimoto C, Hattori N, Watanabe K, Tamada T, Akazawa K, Tanaka T, Nakata K. Kitamura N, et al. Among authors: akazawa k. Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1182-1189. doi: 10.1002/pds.4259. Epub 2017 Jul 28. Pharmacoepidemiol Drug Saf. 2017. PMID: 28752672 Clinical Trial.
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K; Japanese Serous Ovarian Cancer Study Group. Yoshihara K, et al. Among authors: akazawa k. Clin Cancer Res. 2012 Mar 1;18(5):1374-85. doi: 10.1158/1078-0432.CCR-11-2725. Epub 2012 Jan 12. Clin Cancer Res. 2012. PMID: 22241791
562 results